
NeurologyLive® Brain Games: December 28, 2025
Key Takeaways
- NeurologyLive Brain Games offers weekly quizzes on diverse neurology topics, crafted by field experts.
- Focus areas include dementia, epilepsy, headaches, movement disorders, multiple sclerosis, and more.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of RBD as a prodromal marker for synucleinopathies.
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
Which of the following neurodegenerative disorders has the highest long-term phenoconversion rate among patients initially diagnosed with idiopathic REM sleep behavior disorder (iRBD)?
Which neuropathologic finding most strongly supports idiopathic RBD as a prodromal synucleinopathy?
Which non-motor feature, when present alongside idiopathic RBD, most strongly increases short-term risk of phenoconversion to Parkinson disease or dementia with Lewy bodies?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.




